PAVM Quote, Financials, Valuation and Earnings

Lucid Diagnostics, Inc. has a net margin of -120220% compared to PAVmed, Inc.'s net margin of -858.55%. PAVmed, Inc.'s return on equity of 8.75% beat Lucid Diagnostics, Inc.'s return on equity of -665.25%.

PAVmed, Inc. has a consensus price target of $11.00, signalling upside risk potential of 3352.61%. On the other hand Lucid Diagnostics, Inc. has an analysts' consensus of $3.75 which suggests that it could grow by 260.58%. Given that PAVmed, Inc. has higher upside potential than Lucid Diagnostics, Inc., analysts believe PAVmed, Inc. is more attractive than Lucid Diagnostics, Inc..

PAVmed, Inc. has a beta of 1.095, which suggesting that the stock is 9.503% more volatile than S&P 500. In comparison Lucid Diagnostics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

PAVmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lucid Diagnostics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PAVmed, Inc. pays -- of its earnings as a dividend. Lucid Diagnostics, Inc. pays out -- of its earnings as a dividend.

PAVmed, Inc. quarterly revenues are $5K, which are smaller than Lucid Diagnostics, Inc. quarterly revenues of $1.2M. PAVmed, Inc.'s net income of -$6M is higher than Lucid Diagnostics, Inc.'s net income of -$10.4M. Notably, PAVmed, Inc.'s price-to-earnings ratio is 0.30x while Lucid Diagnostics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PAVmed, Inc. is 283.81x versus 19.76x for Lucid Diagnostics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Myomo, Inc. has a net margin of -120220% compared to PAVmed, Inc.'s net margin of -36.3%. PAVmed, Inc.'s return on equity of 8.75% beat Myomo, Inc.'s return on equity of -68.35%.

PAVmed, Inc. has a consensus price target of $11.00, signalling upside risk potential of 3352.61%. On the other hand Myomo, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 419.7%. Given that PAVmed, Inc. has higher upside potential than Myomo, Inc., analysts believe PAVmed, Inc. is more attractive than Myomo, Inc..

PAVmed, Inc. has a beta of 1.095, which suggesting that the stock is 9.503% more volatile than S&P 500. In comparison Myomo, Inc. has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.583%.

PAVmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PAVmed, Inc. pays -- of its earnings as a dividend. Myomo, Inc. pays out -- of its earnings as a dividend.

PAVmed, Inc. quarterly revenues are $5K, which are smaller than Myomo, Inc. quarterly revenues of $10.1M. PAVmed, Inc.'s net income of -$6M is lower than Myomo, Inc.'s net income of -$3.7M. Notably, PAVmed, Inc.'s price-to-earnings ratio is 0.30x while Myomo, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PAVmed, Inc. is 283.81x versus 0.95x for Myomo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Phibro Animal Health Corp. has a net margin of -120220% compared to PAVmed, Inc.'s net margin of 7.29%. PAVmed, Inc.'s return on equity of 8.75% beat Phibro Animal Health Corp.'s return on equity of 24.77%.

PAVmed, Inc. has a consensus price target of $11.00, signalling upside risk potential of 3352.61%. On the other hand Phibro Animal Health Corp. has an analysts' consensus of $43.00 which suggests that it could grow by 3.89%. Given that PAVmed, Inc. has higher upside potential than Phibro Animal Health Corp., analysts believe PAVmed, Inc. is more attractive than Phibro Animal Health Corp..

PAVmed, Inc. has a beta of 1.095, which suggesting that the stock is 9.503% more volatile than S&P 500. In comparison Phibro Animal Health Corp. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.868%.

PAVmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phibro Animal Health Corp. offers a yield of 1.16% to investors and pays a quarterly dividend of $0.12 per share. PAVmed, Inc. pays -- of its earnings as a dividend. Phibro Animal Health Corp. pays out 40.46% of its earnings as a dividend. Phibro Animal Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

PAVmed, Inc. quarterly revenues are $5K, which are smaller than Phibro Animal Health Corp. quarterly revenues of $363.9M. PAVmed, Inc.'s net income of -$6M is lower than Phibro Animal Health Corp.'s net income of $26.5M. Notably, PAVmed, Inc.'s price-to-earnings ratio is 0.30x while Phibro Animal Health Corp.'s PE ratio is 24.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PAVmed, Inc. is 283.81x versus 1.21x for Phibro Animal Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis, Inc. has a net margin of -120220% compared to PAVmed, Inc.'s net margin of -86.59%. PAVmed, Inc.'s return on equity of 8.75% beat Stereotaxis, Inc.'s return on equity of -218.3%.

PAVmed, Inc. has a consensus price target of $11.00, signalling upside risk potential of 3352.61%. On the other hand Stereotaxis, Inc. has an analysts' consensus of $4.25 which suggests that it could grow by 82.4%. Given that PAVmed, Inc. has higher upside potential than Stereotaxis, Inc., analysts believe PAVmed, Inc. is more attractive than Stereotaxis, Inc..

PAVmed, Inc. has a beta of 1.095, which suggesting that the stock is 9.503% more volatile than S&P 500. In comparison Stereotaxis, Inc. has a beta of 1.472, suggesting its more volatile than the S&P 500 by 47.244%.

PAVmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PAVmed, Inc. pays -- of its earnings as a dividend. Stereotaxis, Inc. pays out -- of its earnings as a dividend.

PAVmed, Inc. quarterly revenues are $5K, which are smaller than Stereotaxis, Inc. quarterly revenues of $7.5M. PAVmed, Inc.'s net income of -$6M is higher than Stereotaxis, Inc.'s net income of -$6.5M. Notably, PAVmed, Inc.'s price-to-earnings ratio is 0.30x while Stereotaxis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PAVmed, Inc. is 283.81x versus 6.87x for Stereotaxis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.